XXXX is effective for minimizing @entity2224 in cardiac surgery.

@entity1 @entity3175 @entity8162 @entity3303 @entity2224 @entity955 @entity6305 @entity5161 @entity943 @entity3575
@entity8162 was added to cardioplegia and studied for its efficacy in stabilizing the postischemic rhythm after aortic declamping in cardiac surgery. Fifty-six @entity1 scheduled for coronary artery bypass grafting (CABG), were included in a randomized, double-blind study. The @entity1 were anesthetized with @entity5161 , low-dose @entity3575 , @entity3175 , and @entity6305 . In the study group (28 @entity1 ), St. Thomas' Hospital cardioplegic solution II (Plegisol) was prepared with 1 mM @entity8162 . The control group (28 @entity1 ) was given the same cardioplegia with saline. @entity2224 ( @entity2224 ) occurring after declamping was treated with direct current (DC) shock (8-12-12-20 J). There were no significant differences with regard to demographic properties or anesthesiologic and surgical treatment. Two @entity1 (7%) in the @entity8162 group required DC shock for @entity2224 , compared to 28 (100%) in the control group (P < 0.001). The amount of @entity3303 (mean +/- SEM) given for resistant @entity943 was 3.6 mg +/- 3.6 in the @entity8162 group compared to 35.7 mg +/- 9.2 in the control group (P < 0.002). One @entity1 in each group required temporary pacing. The number of synchronized DC shocks for conversion of @entity955 was lower in the @entity8162 group (P < 0.05). The enzyme release the first day after surgery was lower in the @entity8162 group (P < 0.05). @entity8162 (1 mM) in cardioplegia stabilizes the postischemic rhythm in CABG surgery in @entity1 without any observed adverse effects.
